NOVEL NANOPARTICLES FOR THE ORAL DELIVERY OF LOW MOLECULAR WEIGHT HEPARIN: IN VITRO AND IN VIVO ASSESSMENT

LAVANYA NALLAGUNTLA¹, INDIRA MUZIB Y¹, JITHAN AUKUNURU², UMAMAHESH BALEKARI³

¹Department of Pharmaceutics, Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visavidyalyam (Womens university), Tirupathi, Andhra Pradesh, India. ²Department of Pharmaceutics, Mother Teresa College of Pharmacy, Hyderabad, Telangana, India. ³Aizant Drug Solutions Pvt. Ltd., Hyderabad, Telangana, India. ⁴Department of Pharmacognosy, Faculty of Pharmacy, University College of Pharmaceutical Sciences, Kakatiya University, Warangal, Telangana, India. Email: lavanyanallaguntla@gmail.com

ABSTRACT

Objective: The objective of the present study was to prepare and evaluate a novel oral formulation of nanoparticles for the systemic delivery of low-molecular-weight heparin (LMWH).

Methods: Nanoparticles were prepared by polyelectrolyte complexation method using polymers, i.e., sodium alginate and chitosan (CH). Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), X-ray diffraction (XRD), entrapment efficiency, In vitro release and scanning electron microscopic studies were carried out for nanoparticles. Ex vivo permeation studies were performed with optimized formulation using small intestine of rat and in vivo studies were conducted on rat model.

Results: Entrapment efficiency of LMWH in nanoparticles was found to be 88%. In vitro release studies demonstrated that the release of LMWH was negligible in the stomach and high in the small intestine. FTIR has indicated that there is no interaction between the ingredients in nanoparticle. DSC and XRD studies confirmed that the amino groups of CH interacted with the carboxylic groups of alginate. In vitro % drug release of 95% was shown by formulation ACS. Ex vivo permeation studies have elucidated that ~73% of LMWH was transported across the epithelium. Nanoparticles have shown enhanced oral bioavailability of LMWH as revealed by 4.5-fold increase in area under the curve of plasma drug concentration-time curve.

Conclusion: The results suggest that the nanoparticles prepared can result in targeted delivery of LMWH into systemic circulation through intestinal and colon routes. Novel nanoparticles thus prepared in this study can be considered as a promising delivery system.

Keywords: Antifactor Xa activity, Chitosan, Differential scanning calorimetry, Sodium alginate, Low-molecular-weight heparin, Oral bioavailability.

INTRODUCTION

Low-molecular-weight heparin (LMWH) is used as an anticoagulant in mostly two common post-surgical complications such as deep vein thrombosis and pulmonary embolism. It is used for long-term dosing through parenteral route and hence has reduced patient compliance. This can be improved by administering LMWH through the oral route. However, its clinical application through oral route is limited because of its large molecular size, high negative charge, instability in gastrointestinal region, and high water solubility. However, several studies addressed oral delivery of LMWH into systemic circulation. Various approaches have been investigated such as microemulsions, nanoparticles, microparticles, pellets, and chemical conjugates [1-5]. Yet, no oral formulation is able to produce good oral bioavailability and is not available in the market yet now. Since LMWH is permeable in the lower small intestine and colon, its penetration enhancement can be conveniently used to produce a market viable oral formulation for LMWH. Subsequently, in the present study, attempts were made to prepare and evaluate LMWH nanoparticles.

Nanoparticles were selected as they have the following advantages (a) they offer protection against acidic environment and enzymatic degradation, (b) its small size and the bioadhesive polymers used help in prolonging the gastric transit and permeating the mucous membrane. Particle size (1000 nm) is considered as a crucial parameter for bioadhesion and adsorption through the mucosal membrane. Paracellular and endocytic pathway are the major transport mechanisms for the transport of nanoparticles which majorly depended on particle size [6]. Various types of nanoparticles have been studied earlier [7,8]. Polyelectrolyte complexation (PEC) method is selected for preparation of nanoparticles as these are considered as the emerging delivery systems for the oral delivery of proteins, nucleic acids [9,10], etc. A combination of chitosan (CH) and alginate was used as the polyelectrolyte combination. Previously studies indicated that such nanoparticles are gastric resistant. Further, the natural bioadhesive property of the combination can lead to more residence on the mucosal membrane which in turn can result in significant systemic LMWH.

PEC is formed by spontaneous interaction of oppositely charged polysaccharides in aqueous solution. Polysaccharides are of particular importance due to their desirable biocompatible, biodegradable, hydrophilic, and protective properties. PEC method has the advantage of not using sonication and organic solvents which are harmful for proteins and polysaccharides. Previous investigations confirmed that CH and alginate were widely used for PEC formation and they have profound applications in drug or gene delivery systems in biomedicine [11,12].

CH is a linear polysaccharide composed of randomly distributed β-(1→4)-linked D-glucosamine (deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit) [13]. It is a biocompatible, biodegradable polymer, having inherent mucoadhesive properties with the capacity to open tight junctions in the mucosal membrane. The positive charge of
CH forms a strong bond with the negatively charged epithelial lining of the gastrointestinal tract. This high interaction helps in opening the tight junction and makes the drug to reach the systemic circulation. However, it is mostly soluble in acidic pH conditions of the stomach, which makes it to lose its mucoadhesive and permeation enhancing properties. To overcome this, in the present study, a complex was formed between CH and a natural polyanion to improve the physicochemical property of CH. One of the polyanionic polymers that are widely used is sodium alginate (SA).

SA is an anionic polysaccharide distributed widely in the cell walls of brown algae. It is a linear copolymer with homopolymeric blocks of (1-4)-linked β-D-mannurionate (M) and its C-5 epimer α-L-guluronic acid (G) residues, covalently linked together in different sequences or blocks. The negatively charged carboxylic acid groups of mannuronic and guluronic acid units of alginate interact electrostatically with positively charged amino groups of CH to form polyelectrolyte. At a pH of 2.5, SA is negatively charged. As the pH increases from 2.5, the number of anionic charges on the SA is increased. While at pH <6.5, CH is positively charged. The pH values, i.e. 4.0 for CH and 6.5 for SA ensures an increased charge density on each polymer and leads to intense cross-linking on mixing [14]. SA is mostly used as polyelectrolyte that forms complex with CH because the complex formed between the polymers is still biodegradable, biocompatible, and mechanically stronger in acidic pH conditions where CH dissolves. A research work has demonstrated that CH alone was effectively degraded by lysozymes [15,16]. However, this enzyme effect on PEC is negligible because of the strong interaction between the two polymeric chains.

In this study, PEC is formed by one-stage process. In this method, one polymer solution of a particular pH is added dropwise to the other polymer solution of a certain pH under high shearing conditions. In the present work, LMWH loaded PEC nanoparticles were formulated and it's *in vitro* and *in vivo* absorption are compared with LMWH CH nanoparticles. Such nanoparticles for oral delivery of LMWH were not reported previously.

**MATERIALS AND METHODS**

**Materials**

Enoxaparin sodium (LMWH) was purchased from Bharath Biotech, Hyderabad, India. CH, sodium tripolyphosphate (STPP), dialysis membrane (MW 12,000 Da), and cetyl pyridinium chloride were purchased from Sigma-Aldrich Private Limited, Mumbai, India. SA was purchased from SD Fine Chemicals Limited, Gujarat, India. Stachrom Heparin supplied by Diagnostica Stago, Asnieres-sur-Seine, France. All the other chemicals and reagents were of analytical grade and used as supplied. Simulated gastric fluid (pH 1.2) was prepared by adding reagents and reacted for 1 hr. The release study was performed for 24 hrs. Aliquots of 0.5 ml were taken at regular intervals, i.e. 1, 2, 3, 4, 5, 6, 8, 10 up to 24 hrs and analyzed by using UV-visible spectrophotometer at 500 nm. The experiment was performed for plain CH nanoparticles and analyzed.

**Preparation of CH nanoparticles**

Nanoparticles were prepared by ion gelation of CH with STPP aqueous solution. First, CH was dissolved in 1% solution of acetic acid. LMWH was then added to CH solution and mixed. Aqueous solution of STPP was added dropwise to CH solution by magnetic stirring at room temperature using high-speed homogenizer [18].

**Preparation of PEC nanoparticles of alginate and CH**

SA solution was prepared by dissolving SA in reverse osmosis (RO) water. CH solution was prepared by dissolving CH in 1% acetic acid solution. Both the solutions were placed separately on magnetic stirrer at 100 rpm for 1 hr. CH solution (20 mg) was then added to SA solution and dissolved. SA solution was adjusted to pH 6.5 and CH solution to pH 4.0. SA solution is then slowly added to CH solution at a flow rate of 1 ml/s with the help of high-speed homogenizer (Unidrive X1000D Homogenizer drive, CAT’s scientific laboratory, California) at 10,000 rpm. Alginate in CH PECs was thus formed [10].

**Preparation of CH nanoparticles**

Nanoparticles were prepared by ion gelation of CH with STPP aqueous solution. First, CH was dissolved in 1% solution of acetic acid. LMWH was then added to CH solution and mixed. Aqueous solution of STPP was added dropwise to CH solution by magnetic stirring at room temperature using high-speed homogenizer [18].

**In vitro characterization of PEC nanoparticles**

PEC nanoparticles and its formulation components were subjected to Fourier transform infrared (FTIR) (Bruker Alpha-E spectrophotometer, Ettlingen, Germany), differential scanning calorimetry (DSC) (automatic thermal analyzer, DSC 910S, TA Instruments, America), X-ray diffraction (XRD) (X'Pert PRO multipurpose X-ray diffractometer, PANalytical, Tokyo, Japan), scanning electron microscopy (LEO 435 VP, Eindhoven Netherlands), and particle size and zeta potential studies (Zetasizer, Model 3000 HSA, Malvern Instrument, WR14 1XZ, UK).

**Entrapment efficiency (EE)**

The EE of LMWH in PEC nanoparticles was performed by an indirect method. The amount of unentrapped LMWH in the nanoparticles suspension was analyzed by taking the supernatant after centrifugation at 15000 rpm for 20 minutes. Then, aliquots of 1 ml of the supernatant was taken and mixed with reagents as discussed previously in the methods and reacted for 1 hr. Later, the absorbance of these samples was taken at 500 nm using UV-visible spectrophotometer. The study was performed in triplicate, and the percentage EE was determined [19].

\[
\text{EE} = \frac{\text{Totalamount ofLMWHtaken} - \text{FreeLMWHinthesupernatant}}{\text{Totalamount ofLMWHtaken}} \times 100
\]

**Percentage transmittance**

The study was performed 1-3 hrs after the preparation of PECs. RO water was used as the blank and adjusted to 100% transmittance at 800 nm using UV-visible spectrophotometer [10]. The % transmittance of PEC nanoparticles was then measured.

**In vitro release study**

The *in vitro* release study of LMWH from drug loaded PEC nanoparticles was performed using the dialysis membrane method. LMWH PEC nanoparticulate suspension was filled in a dialysis bag (MW-12,000 Da) which was attached to a two-end opened boiling tube [20]. The boiling tube was then dipped in a beaker containing 50 ml of pH 1.2 buffer and placed on a magnetic stirrer for 2 hrs at 37±0.5°C and 50 rpm. The medium was then replaced with pH 7.4 buffer and after 3 hrs with pH 7.4 buffer. The release study was performed for 24 hrs. Aliquots of 0.5 ml were taken at regular intervals, i.e. 1, 2, 3, 4, 5, 6, 8, 10 up to 24 hrs and analyzed by using UV-visible spectrophotometer at 500 nm. The experiment was performed for plain CH nanoparticles and analyzed.

**Ex vivo drug release study**

The amount of LMWH transported across the intestinal barrier was measured. Small intestine of male Wistar rat was removed and rinsed with normal saline solution. LMWH loaded PEC nanoparticulate suspension was filled in the membrane, and both ends were tied with a thread separately and fixed to a stand. The membrane was then introduced into 50 ml of 6.8 pH buffer in a beaker. The beaker was then placed on a magnetic stirrer at 37°C and 100 rpm. Aliquots of 1 ml were taken at intervals of 5, 15, 30, 45, 60, 90, 120 minutes up to 8 hrs. The samples were then analyzed by UV-visible spectrophotometer at 500 nm by the addition of reagents and reacted for 1 hr. Permeation studies were performed in triplicate [21].
Stability studies

The LMWH loaded PEC nanoparticles were studied for stability studies at various temperatures such as 4±1°C and 25±1°C and examined at regular time intervals for any change in particle size and drug content [19].

Oral absorption studies in rats

All animal studies were approved by the Institutional Ethical Committee, Warangal, registered under CPCSEA, India (IAEC no. 1047/ac/07/CPCSEA). Male Wistar rats (weighting 130±20 g) were taken and fastened overnight with free access to water before the administration of formulations. Three groups of animals were taken, each group containing six animals. Group 1 is considered as control which was a plain LMWH solution (50 mg/kg) and given orally to rats. Formulations such as LMWH loaded plain CH nanoparticulate suspension and PEC nanoparticles were administered orally to Group 2 and Group 3 rats, respectively, in the same dose. To Group 3, LMWH loaded PEC nanoparticles were administered orally in the same dose. Blood samples were withdrawn from the retro-orbital plexus at 0, 1, 2, 3, 4, and 5 up to 8 hrs. LMWH was quantified using an anti-factor Xa chromogenic assay. Anti-factor Xa activity versus time profile of LMWH in the plasma was then plotted and compared with that of the oral LMWH solution. Plasma concentrations of the drug were estimated, and different pharmacokinetic parameters were evaluated. Clotting time studies were performed with a plain LMWH solution, LMWH CH nanoparticles, and LMWH PEC nanoparticles on Wistar rats using a laboratory method as specified in reference [22,23].

Briefly, formulations were administered to three groups of animals as mentioned above. At regular time intervals, i.e. 0, 1, 2, 3, 4 up to 8 hrs blood samples were collected and their clotting time was determined by capillary method.

RESULTS

PECs were frequently prepared by mixing two electrolyte solutions of opposite charges. Various quantities of alginate and CH were taken at desirable pH conditions and complexes were prepared (Table 1). The formation of PECs was confirmed by FTIR and DSC studies. From the FTIR spectrum of LMWH loaded PEC nanoparticles; it was observed that the asymmetric and symmetric carboxylate anion (COO−) stretching was shifted from 1661 to 1638/cm and from 1450 to 1439/cm, respectively. Furthermore, the absorption band of CH was shifted from 1582 to 1546/cm and the broadening of band from 1510 to 1400/cm was attributed to the overlapping of amide of CH with carboxyl anion of alginate (Table 2). No characteristic bands of LMWH were observed in the spectrum of nanoparticulate formulation (Fig. 1). DSC confirms the presence of interaction between CH and alginate. As observed from the thermograms shown in Fig. 2, the endotherms of CH and SA were exhibited at 111.63°C and 130°C which indicates the evaporation of absorbed water. An endotherm of PEC nanoparticles was observed at 99.6°C which is lower than the endothermic peaks of CH and SA individually. This indicates that the hydrophilic groups in the PECs were more exposed possibly due to the formation of gaps after complexation. Exothermic peaks registered in 320.54°C, 253.58°C, and 281.4°C for CH, SA, and PEC nanoparticles, respectively, indicate that PEC nanoparticles have a peak value intermediate between the peaks of SA and CH.

This peak value was interpreted as an interaction between the two polymers [24]. XRD spectra of PEG nanoparticles have shown the presence of 2 peaks of SA and a large bump. This indicates that SA was exposed on the outer surface and concealed the CH groups. The large bump indicates the entrapment of drug and formation of PEC (Fig. 3).

Two types of nanoparticles were prepared, i.e., PEC nanoparticles and CH nanoparticles. CH nanoparticles were only used for comparison, in in vitro and in vivo studies. Morphology of the PEC nanoparticles was determined by scanning electron microscopy (SEM) study. The shape of the PEC nanoparticles was found to be almost spherical (Fig. 4).

From the Table 1, it was observed that most of the alginate (AG), CH PEC nanoparticles have good % entrapment efficiencies. With increase in concentration of CH, the EE was increased. This was because of the increased number of complexes that are formed between CH and AG. The formulation AC6 has shown higher % EE. One of the reasons behind this is the interaction of CH with AG, and the other was the interaction of CH with LMWH which was negatively charged leading to higher EE. For obtaining a qualitative measure of the size of PECs, percentage transmittance studies were performed for formulations AC3 to AC9 at 800 nm. At this wavelength, both AG and CH do not absorb any light [10]. Decrease in % transmittance was a measure of increased particle size (Table 3). This may be because of the repulsion between the excess positive charges provided by the CH molecule in nanoparticles.

From the in vitro release studies, it was observed that <1% of drug was released within 2 hrs in pH 1.2 buffer (Fig. 5). The complex was tough enough in the stomach because of the insolubility of AG at the particular pH [25]. In pH 6.8 and pH 7.4 buffer, a constant release of the LMWH was observed with a maximum release of 90% of the initial amount. CH nanoparticles have shown 31.45% release of the drug in 1.2 pH buffer, which was not seen in PEC nanoparticles. The results of release kinetics revealed that the mode of drug release from PEC nanoparticles followed the Higuchi model with r²=0.8654 (Table 4). Data were also fitted into the Korsmeyer–Peppas equation to determine the drug release mechanism further.

The n value indicates super case-II transport [26]. Formulation AC3 was considered less stable as it has shown aggregation and increased particle size within 10 days. Taking into consideration EE, in vitro release the formulations AC4, AC5, AC7, and AC8 were evaluated for particle size, zeta potential, and polydispersity index (Table 5). Particle size was found to increase with increase in CH concentration. The zeta potential values have shown a shift in charge on the surface of nanoparticles from higher to lower negative values. Polydispersity

| Formulation | LMWH (mg) | CH (mg) | SA (mg) | Acetic acid (%v/v) | Water (ml) | % EE |
|-------------|-----------|---------|---------|-------------------|------------|------|
| AC1         | 20        | 100     | 100     | 1                 | 100        | 45.5±2.65% |
| AC2         | 20        | 200     | 100     | 1                 | 100        | 50.5±2.73% |
| AC3         | 20        | 200     | 100     | 1                 | 100        | 77.25±0.68% |
| AC4         | 20        | 300     | 150     | 1                 | 100        | 72.26±1.1% |
| AC5         | 20        | 300     | 250     | 1                 | 100        | 84.88±0.87% |
| AC6         | 20        | 300     | 400     | 1                 | 100        | 88.15±0.9% |
| AC7         | 20        | 350     | 150     | 1                 | 100        | 67.43±0.48% |
| AC8         | 20        | 350     | 200     | 1                 | 100        | 88.86±0.63% |
| AC9         | 20        | 400     | 300     | 1                 | 100        | 87.26±0.7% |
| AC10        | 20        | 500     | 100     | 1                 | 100        | Viscous fibrous preparation |
| AC11        | 20        | 500     | 200     | 1                 | 100        | Viscous fibrous preparation |
| AC12        | 20        | 500     | 300     | 1                 | 100        | Viscous fibrous preparation |

Data are expressed as mean±SD (n=3). SD: Standard deviation, LMWH: Low molecular weight heparin, CH: Chitosan, SA: Sodium alginate, EE: Entrapment efficiency. PEC: Polyelectrolyte complexation
index values <0.5 indicate that the formulation was homogeneous in nature.

In the results of ex vivo studies, 73% and 62% of the drug were found to cross the intestinal membrane for AC4 and AC5 formulations, respectively, and reach the buffer in 6 hrs time period (Fig. 6). The optimized nanoparticle formulation was subjected to stability studies at different storage temperatures in terms of particle size and EE. The nanoparticles showed better stability at 4°C than at 25°C in terms of increased particle size and decreased EE (Table 6).
Table 2: Important band frequencies in FTIR spectrum of drug, pure polymer, and nanoparticle

| Wave number (cm$^{-1}$) | Interpretation                                      |
|-------------------------|-----------------------------------------------------|
| Pure SA                 |                                                     |
| 3279                    | O-H stretch                                         |
| 2946                    | C-H stretch                                         |
| 1661                    | Asymmetric carboxylate anion (COO$^{-}$) stretch     |
| 1450                    | Symmetric carboxylate anion (COO$^{-}$) stretch      |
| 1252                    | C-O stretch                                         |
| 1145                    | Bridge-O-stretch                                    |
| 997                     | C-O-C stretch due to saccharide structure            |
| Pure CH                 |                                                     |
| 3247                    | O-H stretch and N-H stretch                         |
| 2928                    | C-H stretch                                         |
| 1652                    | Amide I NH CO stretch                               |
| 1582                    | Amide II N-H bend                                   |
| 1435                    | C-N stretch                                         |
| 1150                    | Bridge-O-stretch                                    |
| 1010                    | C-O stretch                                         |
| LMWH                    |                                                     |
| 3398                    | O-H stretch                                         |
| 1607                    | N-H broadening                                      |
| 1418                    | C-H stretch of methyl group                         |
| 1217                    | C-O stretch                                         |
| 987                     |                                                     |
| PEC nanoparticles of LMWH|                                                     |
| 3335                    | O-H stretch                                         |
| 2932                    | C-H stretch                                         |
| 1638                    | Asymmetric carboxylate anion (COO$^{-}$) stretch     |
| 1546                    | Amide II N-H bend                                   |
| 1439                    | Symmetric carboxylate anion (COO$^{-}$) stretch      |
| 1152                    | Bridge-O-stretch                                    |
| 1002                    | C-O-C stretch                                       |

Pharmacokinetic parameters were determined from the plasma concentration-time profile of different formulations (Table 7).

For LMWH plain oral solution, the $C_{\text{max}}$ value was observed to be $0.10 \pm 0.007$ IU/ml after 2 hrs of oral administration, while administration of CH nanoparticles enhanced the $C_{\text{max}}$ to $0.16 \pm 0.02$ IU/ml.
the maximum value was observed for LMWH loaded PEC nanoparticles, which was 0.45±0.03 IU/ml. Similarly, area under the curve (0-8 h) of LMWH was increased by 1.8 times for LMWH CH nanoparticles and 4.5 times for LMWH PEC nanoparticles when compared with a plain oral LMWH solution (Fig. 7). The results of clotting time studies have revealed an enhancement in clotting time (Fig. 8).

**DISCUSSION**

FTIR and DSC studies confirmed that the PEC was formed between AG and CH. DSC and XRD studies indicated that AG and CH were transformed to amorphous forms on complexation and LMWH was entrapped. SEM studies revealed that the formed nanoparticles were of spherical shape and the micrographs did not show the appearance of aggregated particles. Based on % EE and % transmittance studies, the formulations AC4, AC5, AC6, AC7, and AC8 were optimized. In vitro release studies indicate that PEC nanoparticles were successful in retarding the release of drug in acidic pH conditions and capable of releasing 90% of the drug in simulated intestinal fluid within 10 hrs time period. This release of LMWH in small intestine could be because of the interaction of AG with alkaline media and an increase in the solubility of AG [27].

The possible mechanism of drug release from LMWH PEC nanoparticles was found to be super case-II transport, which was considered as swelling-controlled release. It was observed that with an increase in concentration of CH the particle size was increased and the zeta potential value has shifted toward lower negative charges. The negative charge demonstrates that AG has formed complex with CH and helped in concealing CH from degradation in the gastric environment. Ex vivo permeation studies indicated that the enhanced transport of PEC nanoparticles was ascribed to the mucoadhesive property of CH and the size of nanoparticles [28].

One of the research articles demonstrated that LMWH loaded trimethyl CH nanoparticles have shown 2.4 times bioavailability of LMWH in comparison to plain LMWH solution [19]. Pharmacokinetic studies of the present study have shown an enhancement in oral bioavailability of LMWH by 4.5 times when compared with a plain LMWH solution. This enhanced oral bioavailability was attributed to the interaction of AG and CH, which prevented the degradation of drug in gastric fluid. PEC nanoparticles then enter the small intestine where the AG gets slowly dissolved exposing the amino groups of CH. These amino groups get attached to the negative charge of epithelial lining and help with paracellular transport across the intestinal epithelium. This results in delivery of the drug to systemic circulation without damaging the intestinal epithelium. The in vitro and in vivo evaluation of PEC nanoparticles demonstrates that the

**Table 3: Percentage transmittance study of alginate/CH formulations**

| Alginate/CH formulations | AC3 | AC4 | AC5 | AC6 | AC7 | AC8 | AC9 |
|--------------------------|-----|-----|-----|-----|-----|-----|-----|
| Percentage transmittance | 90±1.23% | 94±2.6% | 92±1.79% | 84±3.21% | 89±1.4% | 90±2.9% | 80±1.1% |

Data are expressed as mean±SD (n=3). SD: Standard deviation, CH: Chitosan

**Table 4: Comparison of estimated parameters deduced from in vitro LMWH release curve of PEC nanoparticles in mixed pH media by fitting to various kinetic models**

| Formulation | Zero order | First order | Higuchi model | Hixon- crowell | Korsmeyer Peppas |
|-------------|------------|------------|--------------|---------------|------------------|
|              | r²         | r²         | r²           | r²            | n                |
| AC3         | 0.4821     | 0.5692     | 0.8774       | 0.1753        | 0.9917           | 1.21            |
| AC4         | 0.3991     | 0.4054     | 0.8654       | 0.1759        | 0.9802           | 0.89            |
| AC5         | 0.5537     | 0.8772     | 0.9112       | 0.2862        | 0.9935           | 1.07            |
| AC7         | 0.6029     | 0.5524     | 0.9019       | 0.2862        | 0.9848           | 1.51            |
| AC8         | 0.5833     | 0.7472     | 0.8965       | 0.1926        | 0.9903           | 1.32            |

Data are expressed as mean±SD (n=3). SD: Standard deviation, LMWH: Low-molecular-weight heparin, PEC: Polyelectrolyte complexation

**Table 5: Particle size, zeta potential, and polydispersity index of LMWH loaded PEC nanoparticles**

| Formulation | Particle size | Zetapotential | Polydispersity index |
|-------------|---------------|---------------|---------------------|
| AC4         | 119±1.3 nm    | -22±0.6       | 0.25±0.02           |
| AC5         | 142±0.8 nm    | -08±0.4       | 0.33±0.03           |
| AC7         | 195±0.3 nm    | -24±0.8       | 0.41±0.01           |
| AC8         | 255±2.5 nm    | -12±0.2       | 0.11±0.06           |

Data are expressed as mean±SD (n=3). SD: Standard deviation, LMWH: Low-molecular-weight heparin, PEC: Polyelectrolyte complexation

**Fig. 6: Cumulative percent transport of low molecular weight heparin from polyelectrolyte complexation nanoparticles AC4 and AC5. Data represent mean±standard deviation (n=6)**

**Fig. 7: Antifactor Xa activity profile of low-molecular-weight heparin (LMWH) oral solution, LMWH chitosan nanoparticles, and LMWH polyelectrolyte complexation nanoparticles after oral administration in equivalent dose of 50 mg/kg in Wistar rats. Data represent mean±standard deviation (n=6)**

---

**Table 3: Percentage transmittance study of alginate/CH formulations**

**Table 4: Comparison of estimated parameters deduced from in vitro LMWH release curve of PEC nanoparticles in mixed pH media by fitting to various kinetic models**

**Table 5: Particle size, zeta potential, and polydispersity index of LMWH loaded PEC nanoparticles**

---

**Fig. 6:** Cumulative percent transport of low molecular weight heparin from polyelectrolyte complexation nanoparticles AC4 and AC5. Data represent mean±standard deviation (n=6)

**Fig. 7:** Antifactor Xa activity profile of low-molecular-weight heparin (LMWH) oral solution, LMWH chitosan nanoparticles, and LMWH polyelectrolyte complexation nanoparticles after oral administration in equivalent dose of 50 mg/kg in Wistar rats. Data represent mean±standard deviation (n=6)
The approach to the oral delivery of LMWH is of utmost importance to prevent the invasive delivery. CH nanoparticles can be considered for oral delivery, but the high solubility of CH in acidic pH conditions makes it less suitable for oral administration. Hence, PEC nanoparticles were developed with AG and CH to overcome the limitations associated with plain CH nanoparticles. The developed PEC nanoparticles have shown an enhanced oral bioavailability in comparison with a plain LMWH nanoparticle. The developed PEC nanoparticles have shown an enhanced oral bioavailability in comparison with a plain LMWH nanoparticle. The developed PEC nanoparticles have shown an enhanced oral bioavailability in comparison with a plain LMWH nanoparticle. The developed PEC nanoparticles have shown an enhanced oral bioavailability in comparison with a plain LMWH nanoparticle. The developed PEC nanoparticles have shown an enhanced oral bioavailability in comparison with a plain LMWH nanoparticle. The developed PEC nanoparticles have shown an enhanced oral bioavailability in comparison with a plain LMWH nanoparticle. The developed PEC nanoparticles have shown an enhanced oral bioavailability in comparison with a plain LMWH nanoparticle. The developed PEC nanoparticles have shown an enhanced oral bioavailability in comparison with a plain LMWH nanoparticle. The developed PEC nanoparticles have shown an enhanced oral bioavailability in comparison with a plain LMWH nanoparticle.

REFERENCES

1. Andersson M, Löfroth JE. Small particles of a heparin/chitosan complex prepared from a pharmaceutically acceptable microemulsion. Int J Pharm 2003;257(1-2):305-9.
2. Wang J, Tan H, Yu A, Ling P, Lou H, Zhai G, et al. Preparation of chitosan-based nanoparticles for delivery of low molecular weight heparin. J Biomed Nanotechnol 2011;7(5):696-703.
3. Ayus Y, Ferhan S. An overview of modified release chitosan, alginate and Eudragit RS microparticles. J Chem Pharm Res 2010;2(3):704-21.
4. Scala-Bertola J, Gajdziok J, Rabisková M, Bonneaux F, Lecompte T, Sapin A, et al. Polyelectrolyte complexation, CH: Chitosan

nanoparticulate system can be considered as a useful oral delivery system for enhancing the bioavailability of LMWH.

CONCLUSION

The authors acknowledge the Principal and Management of Vaagdevi College of Pharmacy, Hanamkonda, Sri Padmavathi Mahila Vishwavidyalayam, Tirupati, for providing the necessary facilities helpful in the conduct of the work.

ACKNOWLEDGMENTS

Table 6: Effect of storage temperature on particle size and EE of LMWH loaded PEC nanoparticles

| Formulation      | Particle size (nm) | EE (%) | Storage temperature |
|------------------|--------------------|--------|---------------------|
|                  | 0 day Room temperature | After 60 days | 0 day Room temperature | After 60 days |
|                  | 4±1°C | 25±1°C | 4±1°C | 25±1°C |
| PEC nanoparticle | 105±1.3 | 119±3.9 | 276±2.6 | 80±3.4 |
|                  | 4.24±0.012 | 0.31±0.006 | 0.72±0.03 | 0.45±0.03 |
|                  | 0.16±0.02 | 0.56±0.002 | 2.81±0.014 | 1.397±0.24 |
|                  | 74±2.1 | 66±4.2 | 105±1.3 | 105±1.3 |

Data are expressed as mean±SD (n=3). SD: Standard deviation, LMWH: Low-molecular-weight heparin, PEC: Polyelectrolyte complexation, EE: Entrapment efficiency

Table 7: Pharmacokinetic parameters of LMWH nanoparticles after oral administration in Wistar rats

| Pharmacokinetic parameters | LMWH oral solution | LMWH CH nanoparticle | LMWH PEC nanoparticle |
|----------------------------|--------------------|----------------------|-----------------------|
| Dose (mg)                  | 10                 | 10                   | 10                    |
| C_{max} (IU/ml)            | 0.10±0.007         | 0.16±0.02            | 0.45±0.03             |
| T_{1/2} (h)                | 2                  | 4                    | 4                     |
| AUC\_max (µg h/ml)         | 0.31±0.006         | 0.56±0.04            | 1.397±0.24            |
| MRT (hr)                   | 2.8±0.014          | 4.24±0.012           | 4.36±0.11             |
| t_{max} (hr)               | 0.5±0.002          | 0.7±0.03             | 0.74±0.06             |

Data are expressed as mean±SD (n=6). MRT: Mean residence time, AUC: Area under the curve, LMWH: Low-molecular-weight heparin, PEC: Polyelectrolyte complexation, CH: Chitosan

Fig. 8: Clotting time profile of low molecular weight heparin (LMWH) oral solution, LMWH chitosan nanoparticles and LMWH polyelectrolyte complexation nanoparticles after oral administration in equivalent dose of 50 mg/kg in wistar rats. Data represents mean±standard deviation (n=6)
17. Hoffart V, Ulbrich B, Simonin C, Babak V, Vigneron C, Hoffman M, et al. Low molecular weight heparin-loaded polymeric nanoparticles: Formulation characterization and release characteristics. Drug Dev Ind Pharm 2002;28(9):1091-9.

18. Bagre AP, Jain K, Jain NK. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: In vitro and in vivo assessment. Int J Pharm 2013;456(1):31-40.

19. Paliwal R, Paliwal SR, Agrawal GP, Vyas SP. Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: In vitro and in vivo evaluation. Int J Pharm 2012;422(1-2):179-84.

20. Deepak SN, Veda Hari BN. Optimization, development and evaluation of microemulsion for the release of combination of guaifenesin and phenylephrine. J Appl Pharm Sci 2013;3(9):46-56.

21. Ganeshkumar M, Ponrasu T, Sathishkumar M, Suguna L. Preparation of amphiphilic hollow carbon nanosphere loaded insulin for oral delivery. Colloids Surf B Biointerfaces 2013;103:238-43.

22. García-Manzano A, González-Llaven J, Lemini C, Rubio-Poo C. Standardization of rat blood clotting tests with reagents used for humans. Proc West Pharmacol Soc 2001;44:153-5.

23. Lemini C, Rubio-Poo C, Silva G, García-Mondragón J, Zavala E, Mendoza-Patiño N, et al. Anticoagulant and estrogenic effects of two new 17 beta-aminoestrogens, butolame [17 beta-(4-hydroxy-1-butylamino)-1,3,5(10)-estratrien-3-ol] and pentolame [17 beta-(5-hydroxy-1-pentylamino)-1,3,5(10)-estratrien-3-ol]. Steroids 1993;58:457-61.

24. Rafie A, Alimohammadian MH, Gazori T, Riazi-rad F, Fatemi SM, Parizadeh A, et al. Comparison of chitosan, alginate and chitosan/alginate nanoparticles with respect to their size, stability, toxicity and transfection. Asian Pac J Trop Dis 2014;4(5):372-7.

25. Sarmento B, Ribeiro A, Veiga F, Sampaio P, Neufeld R, Ferreira D. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm Res 2007;24(12):2198-206.

26. Ilango KB, Kavimani S. A systematic review of mathematical models of pharmaceutical dosage forms. Int J Curr Pharm Rev Res 2015;6(1):59-70.

27. Mukhopadhyay P, Chakraborty S, Bhattacharya S, Mishra R, Kundu PP. pH-sensitive chitosan/alginate core-shell nanoparticles for efficient and safe oral insulin delivery. Int J Biol Macromol 2015;72:640-8.

28. Sonaje K, Lin YH, Jiang JH, Wey SP, Chen CT, Sang HW. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials 2009;30(12):2329-39.